Protective Role of Agomelatine via Modulation of TLR4/NF-κB: NLRP3/IL-1β Signaling Pathways in Testosterone-Induced Benign Prostatic Hyperplasia in Rats
December 2025
in “
Naunyn-Schmiedeberg s Archives of Pharmacology
”
Studysummary In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer